Dong-A ST (170900) Stock Overview

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Closerin for active pulmonary and extra-pulmonary tuberculosis; Dulastin and Leucostim for neutropenia in patients receiving myelosuppressive chemotherapy; Eporon for anemia associated with chronic renal failure; Gemcit for non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin for infertility and annovulation; Growtropin II for growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel for breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone for use in functional dyspepsia treatment; Stillen for the treatment of gastritis; Suganon for diabetes treatment; Terizidone for active pulmonary and extra-pulmonary tuberculosis; and Zydena for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high technology medical devices, custom made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.